Research Journal of Medical Sciences
ISSN: Online 1993-6095ISSN: Print 1815-9346
Abstract
Sertoli‐Leydig cell tumors (SLCTs) of ovary represents <0.2% of ovarian cancer. Seen at early stage confined to one ovary in reproductive age group with good prognosis fertility‐sparing surgery is an accepted option. Need for adjuvant chemotherapy and relapse depends on risk factors like advanced stage, poor differentiation, retiform patterns and presence of heterologous elements. In this study, clinical pathological characteristics, management and recurrence of ovarian SLCTs has been noted which might aid to improvise on management of SLCTs. Materials And Methods: A retrospective analysis of 8 patients with SLCTs were done. Clinical features, tumor markers, imaging findings, pathological features, treatment modalities, recurrence and survival were noted. A total of 8 cases were noted. Median age was 24 years, 37.5% patients were postmenopausal. 5 underwent unilateral salpingo‐oophorectomy with infra colic omentectomy. 2 patients had pelvic peritoneal disease underwent debulking of the same. 2 patients had Stage Ia disease, 4 had Stage 1c3 and 2 had Stage 2b. 5 patients received adjuvant chemotherapy with BEP or Paclitaxel and Carboplatin. 2 patients were kept under surveillance. 1 patient had recurrence. With 36 months follow up, 7/8 patients are alive and disease free. SLCTs are a very rare entity of tumors were fertility sparing surgery followed by adjuvant chemotherapy is essential in high risk and advanced cases. A registry which documents these kind of rare tumors would be extremely useful for management and surveillance of these patients.
How to cite this article:
Sumangala Gali, Shruthi Shivdas, V.R. Pallavi and K. Shobha. Sertoli Leydig Cell tumor of Ovary: A Rare Entity.
DOI: https://doi.org/10.36478/10.36478/makrjms.2024.9.111.113
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2024.9.111.113